U.S. markets closed
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • Dow 30

    33,290.08
    -533.37 (-1.58%)
     
  • Nasdaq

    14,030.38
    -130.97 (-0.92%)
     
  • Russell 2000

    2,237.75
    -49.71 (-2.17%)
     
  • Crude Oil

    71.57
    +0.53 (+0.75%)
     
  • Gold

    1,763.10
    -11.70 (-0.66%)
     
  • Silver

    25.83
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1862
    -0.0048 (-0.40%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • GBP/USD

    1.3796
    -0.0128 (-0.92%)
     
  • USD/JPY

    110.1980
    -0.0330 (-0.03%)
     
  • BTC-USD

    35,515.36
    -2,160.53 (-5.73%)
     
  • CMC Crypto 200

    881.21
    -58.74 (-6.25%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Rigel Pharmaceuticals initiates Phase 3 studies of fostamatinib in ITP

Rigel Pharmaceuticals initiated a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP - immune thrombocytopenic purpura. The focus of these clinical studies is to evaluate the potential of fostamatinib to increase the platelet counts of patients with chronic ITP. Fostamatinib may provide a novel therapeutic for the underlying cause of this autoimmune disease of the blood.